Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer

Q: Which IL-16 SNPs were investigated in the study of ovarian cancer risk?

The study evaluated four IL-16 SNPs: rs11556218, rs4778889, rs4072111, and rs1131445.

Q: What method was used to genotype the IL-16 SNPs?

Genotyping was performed using the restriction fragment length polymorphism (PCR-RFLP) method.

Q: Which SNPs showed significant associations with ovarian cancer risk?

rs11556218 and rs4778889 were significantly associated with ovarian cancer risk, with stronger evidence particularly in premenopausal women. rs4072111 and rs1131445 were not significantly associated.

Sep 21, 2026

Upload by River Wang

Single nucleotide polymorphisms (SNPs) of the IL-16 gene have been linked to risk of multiple cancers, yet their relevance to ovarian cancer remained unclear. Using PCR-RFLP, four IL-16 SNPs were genotyped in blood from 413 Central European women (200 cases, 213 controls). rs11556218 and rs4778889 showed significant associations with overall ovarian cancer risk, with effects especially prominent in premenopausal women, and rs4778889 also related to high-grade serous subtypes and endometriosis-related forms.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages18

Reading Time45 min

AccessFree to download

Abstract

Introduction

Article Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer Rafał Watrowski 1,2, Eva Schuster 3, Toon Van Gorp 4,5, Gerda Hofstetter 6, Michael B. Fischer 7,8, Sven Mahner 9,10, Stefan Polterauer 3, Robert Zeillinger 3 and Eva Obermayr 3, * Citation: Watrowski, R.; Schuster, E.; Van Gorp, T.; Hofstetter, G.; Fischer, M.B.; Mahner, S.; Polterauer, S.; Zeillinger, R.; Obermayr, E. Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer. Int. J. Mol. Sci. 2024, 25, 10272. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms251910272 Academic Editors: Consolato M. Sergi, Angelo Ravelli and Luca Pio Received: 1 September 2024 Revised: 21 September 2024 Accepted: 22 September 2024 Published: 24 September 2024 Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Department of Obstetrics and Gynecology, Helios Hospital Muellheim, Teaching Hospital of the University of Freiburg, Heliosweg 1, 79379 Muellheim, Germany; rafal.watrowski@gmx.at 2 Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany 3 Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center-Gynecologic Cancer Unit, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; [eva.schuster@meduniwien.ac.at](eva.schuster@meduniwien.ac.at) (E.S.); [stefan.polterauer@muv.ac.at](stefan.polterauer@muv.ac.at) (S.P.); [robert.zeillinger@muv.ac.at](robert.zeillinger@muv.ac.at) (R.Z.) 4 Division of Gynecologic Oncology, University Hospital Leuven, 3000 Leuven, Belgium; [toon.vangorp@uzleuven.be](toon.vangorp@uzleuven.be) 5 Leuven Cancer Institute, Catholic University of Leuven, 3000 Leuven, Belgium 6 Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; [gerda.hofstetter@meduniwien.ac.at](gerda.hofstetter@meduniwien.ac.at) 7 Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; [michael.b.fischer@meduniwien.ac.at](michael.b.fischer@meduniwien.ac.at) 8 Center for Biomedical Technology, Department for Biomedical Research, Danube University Krems, Dr.-Karl-Dorrek-Straße 30, 3500 Krems, Austria 9 Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [sven.mahner@med.uni-muenchen.de](sven.mahner@med.uni-muenchen.de) 10 Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, 81377 Munich, Germany * Correspondence: [eva.obermayr@muv.ac.at](eva.obermayr@muv.ac.at) Abstract: Single nucleotide polymorphisms (SNPs) of the IL-16 gene have been reported to influence the risk of several cancers, but their role in ovarian cancer (OC) has not been studied. Using the restriction fragment length polymorphism (PCR-RFLP) method, we examined four IL-16 SNPs: rs11556218 (T > G), rs4778889 (T > C), rs4072111 (C > T), and rs1131445 (T > C) in blood samples from 413 women of Central European descent, including 200 OC patients and 213 healthy controls. Among the patients, 62% were postmenopausal, 84.5% were diagnosed in late stages (FIGO IIb-IV), and 73.5% had high-grade serous OC (HGSOC). Minor allele frequencies in controls were 9.2% for rs11556218 (G allele), 13.7% for rs4778889 (C allele), 10.4% for rs4072111 (T allele), and 32.3% for rs1131445 (C allele). We found significant associations of rs11556218 (G vs. T allele: OR 2.76, 95% CI 1.84–4.14, p < 0.0001) with ele

FAQs

Which IL-16 SNPs were investigated in the study of ovarian cancer risk?

The study evaluated four IL-16 SNPs: rs11556218, rs4778889, rs4072111, and rs1131445.

What method was used to genotype the IL-16 SNPs?

Genotyping was performed using the restriction fragment length polymorphism (PCR-RFLP) method.

Which SNPs showed significant associations with ovarian cancer risk?

rs11556218 and rs4778889 were significantly associated with ovarian cancer risk, with stronger evidence particularly in premenopausal women. rs4072111 and rs1131445 were not significantly associated.

Sep 21, 2026

Upload by River Wang